Physician profile
Daniel Xie
NPI 1598384828
$2,447.53
in general payments reported to CMS, 2019-2025
24 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $965 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.89 |
| Education | $208.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $402.00 | 2024-2025 | Tremfya |
| Abbvie INC. | $323.18 | 2024-2025 | |
| Amgen INC. | $273.09 | 2024-2025 | Otezla, Otezla |
| Merz North America, INC. | $179.35 | 2024 | |
| Pfizer INC. | $163.39 | 2024-2025 | |
| Genzyme Corporation | $160.30 | 2024-2025 | |
| Leo Pharma INC. | $138.91 | 2024-2025 | Adbry, Anzupgo |
| Kyowa Kirin, INC. | $119.70 | 2024 | Poteligeo |
| Sun Pharmaceutical Industries INC. | $92.27 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $73.06 | 2024-2025 | Zoryve |
| Ucb, INC. | $62.41 | 2025 | Bimzelx |
| Csl Behring | $58.50 | 2024-2025 | Haegarda |
| Botanix Sb INC | $53.53 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $49.55 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $47.22 | 2024-2025 | Taltz, Ebglyss |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $40.06 | 2025 | Vtama |
| Springworks Therapeutics, INC. | $38.61 | 2025 | Gomekli |
| Dermavant Sciences, INC. | $31.36 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.72 | 2024 | Spevigo |
| Galderma Laboratories, L.P. | $29.73 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $28.26 | 2025 | |
| Janssen Scientific Affairs, LLC | $21.83 | 2024 | Tremfya |
| Incyte Corporation | $16.26 | 2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.24 | 2024 | Duobrii, Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.